KPTI News and Press, Karyopharm Therapeutics Inc. From 02/28/19

Karyopharm Therapeutics Inc. (KPTI) Q4 2018 Earnings Conference Call February 28, 2019 8:30 AM ET Company Participants Ian Karp - Vice President, Investor and Public Relations Michael Kauffman - Chief Executive Officer Mike Mason - Chief Financial Officer Jatin Shah - Senior Vi...

The following slide deck was published by Karyopharm Therapeutics Inc. in conjunction with their 2018 Q4 earnings Read more ...

Karyopharm Therapeutics (NASDAQ: KPTI ): Q4 GAAP EPS of -$0.96 misses by $0.11 . More news on: Karyopharm Therapeutics Inc., Earnings news and commentary, Healthcare stocks news, Read more ...

--  FDA Advisory Committee Votes 8 to 5 Recommending FDA Wait for the Results from the Ongoing Phase 3 BOSTON Study to Make an Approval Decision for Selinexor -- -- Company Working with FDA to Evaluate Best Path Forward as FDA Completes Its Review of Selinexor NDA; Assigned PDU...

Weight Watchers (NYSE: WTW )  -35%  on Q4 earnings . More news on: Weight Watchers International, Inc., e.l.f. Beauty, Dycom Industries Inc., Stocks on the move, Read more ...

Heska (NASDAQ: HSKA ) downgraded to Hold at Benchmark. More news on: Heska Corporation, Karyopharm Therapeutics Inc., Mylan Inc, Healthcare stocks news, Stocks on the move, , Read more ...

NEWTON, Mass., Feb. 26, 2019 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) Oncologic Drugs Advisory Committee (ODAC) met to discuss the New Drug Application (NDA) for ...

The correct attitude of the security analyst toward the stock market might well be that of a man toward his wife. He shouldn’t pay too much attention to what the lady says, but he can’t afford to ignore it entirely. That is pretty much the position that most of us find ourselves...

NEWTON, Mass., Feb. 26, 2019 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced that NASDAQ has halting trading of the Company’s common stock. The U.S. Food and Drug Administration (FDA) Oncologic Drugs Advisory Co...

Karyopharm Therapeutics (NASDAQ: KPTI ) appoints Michael P. Mason as Senior VP, Chief Financial Officer (CFO) and Treasurer. More news on: Karyopharm Therapeutics Inc., Healthcare stocks news, Stocks on the move, Read more ...